Aytu BioPharma (AYTU) vs Quoin Pharmaceuticals (QNRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Aytu BioPharma (AYTU) has outperformed Quoin Pharmaceuticals (QNRX) over the past year, losing 13.5% versus a loss of 44.4%. Over five years, AYTU leads with a -96.1% price change compared with -100.0% for QNRX. Aytu BioPharma is the larger company by market cap ($22.2 million vs $21.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AYTU | QNRX |
|---|---|---|
| Share price | $2.04 | $4.39 |
| Market cap | $22.17M | $21.09M |
| 1-day change | -0.49% | -3.52% |
| YTD return | -21.15% | -68.47% |
| 1-year return | -13.50% | -44.44% |
| 5-year return | -96.13% | -99.99% |
| Forward P/E | 13.16 | — |
| EPS (TTM) | $-1.16 | $-5.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.07 | $41.80 |
| 52-week low | $1.80 | $3.25 |
| Distance from 52-week high | -33.55% | -89.50% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +374.02% | +397.27% |
| Average volume | 34.22K | 541.11K |
| Shares outstanding | 10.87M | 4.80M |
| Employees | 75 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AYTU has outperformed QNRX by 30.9 percentage points over the past year.
About Aytu BioPharma
AYTU stock →Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
About Quoin Pharmaceuticals
QNRX stock →Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
AYTU vs QNRX FAQ
Which is bigger, Aytu BioPharma or Quoin Pharmaceuticals?
Aytu BioPharma (AYTU) is larger, with a market capitalization of $22.17M compared with $21.09M for Quoin Pharmaceuticals (QNRX).
Which stock has performed better over the past year, AYTU or QNRX?
AYTU returned -13.50% over the past 12 months, compared with -44.44% for QNRX (price return, excluding dividends). Past performance does not predict future results.
Are Aytu BioPharma and Quoin Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.